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Abstract
Background: Skeletal related events (SREs) are common in men with metastatic prostate cancer (mPC). Various
methods have been used to identify SREs from claims data. The objective of this study was to provide a framework
for measuring SREs from claims and compare SRE prevalence and cumulative incidence estimates based on
alternative approaches in men with mPC.
Methods: Several claims-based approaches for identifying SREs were developed and applied to data for men aged [greater
than or equal to] 66 years newly diagnosed with mPC between 2000 and 2009 in the SEER-Medicare datasets and followed
through 2010 or until censoring. Post-diagnosis SREs were identified using claims that indicated spinal cord compression
(SCC), pathologic fracture (PF), surgery to bone (BS), or radiation (suggestive of bone palliative radiation, RAD). To measure
SRE prevalence, two SRE definitions were created: ‘base case’ (most commonly used in the literature) and ‘alternative’ in
which different claims were used to identify each type of SRE. To measure cumulative incidence, we used the ‘base case’
definition and applied three periods in which claims were clustered to episodes: 14-, 21-, and 28-day windows.
Results: Among 8997 mPC patients, 46 % experienced an SRE according to the ‘base case’ definition and 43 % patients
experienced an SRE according to the ‘alternative’ definition. Varying the code definition from ‘base case’ to ‘alternative’
resulted in an 8 % increase in the overall SRE prevalence. Using the 21-day window, a total of 12,930 SRE episodes were
observed during follow up. Varying the window length from 21 to 28 days resulted in an 8 % decrease in SRE cumulative
incidence (RAD: 10 %, PF: 8 %, SCC: 6 %, BS: 0.2 %).
Conclusions: SRE prevalence was affected by the codes used, with PF being most impacted. The overall SRE cumulative
incidence was affected by the window length used, with RAD being most affected. These results underscore the
importance of the baseline definitions used to study claims data when attempting to understand relevant clinical events
such as SREs in the real world setting.
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Background
The skeleton is the most common site of metastasis in pa-
tients with advanced solid tumors [1, 2]. Approximately
65–75 % of patients with advanced prostate or breast can-
cer develop bone metastasis during the course of their
disease [3]. Randomized clinical trials (RCTs) have
demonstrated that malignant bone lesions resulting from
metastatic cancer have significant clinical consequences
that contribute substantially to the burden of disease and
reduce quality of life [4–7]. These clinical consequences,
known as bone complications, also commonly referred to
as skeletal related events (SREs), include pathologic frac-
ture (PF), spinal cord compression (SCC), bone palliative
radiotherapy (RAD), and bone surgery (BS).
The Food and Drug Administration (FDA) has desig-
nated SREs as a measurable composite endpoint allow-
ing investigators to evaluate efficacy of drugs to prevent
* Correspondence: aaly001@umaryland.edu
1Department of Pharmaceutical Health Services Research, University of
Maryland, School of Pharmacy, Saratoga Building, 12th Floor, 220 Arch Street,
Baltimore, MD 21201, USA
Full list of author information is available at the end of the article
© 2015 Aly et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Aly et al. BMC Medical Research Methodology  (2015) 15:65 
DOI 10.1186/s12874-015-0047-5
SREs [8]. Zoledronic acid and, more recently, denosu-
mab have been approved by the FDA for the prevention
of SREs based on delaying their onset [9]. When measur-
ing SREs in RCTs to assess clinical burden, a 21-day
window for counting events was imposed whereby any
SRE occurring within 21 days of a previous one was not
counted as a new SRE. This approach is clinically mean-
ingful in the context of a RCT for establishing efficacy
because individual SREs may be serially interdependent.
For example, a bone surgery performed to treat a spinal
cord compression event that occurred within 21 days of
the bone surgery is considered a single SRE.
Studies using administrative claims data have also
demonstrated that patients with bone metastasis and
SREs have high utilization of healthcare resources and
high associated costs [10–16]. Contrary to RCTs, where
measuring SREs is supported by radiologic evaluations
and frequent patient follow up in a prospective fashion, it
is less clear how investigators can accurately identify SREs
from claims data. There are multiple ways in which inves-
tigators have identified SREs using administrative claims,
ranging from approaches that maximized sensitivity of
SRE measures to methods that aimed at higher specificity
for specific SRE subtypes [11–19] (Fig. 1). Moreover, the
potential for misclassification may differ across subcom-
ponents of SREs when using claims data to identify the oc-
currence of an SRE. The accurate identification of an SRE
depends on a reliable approach for identifying both the
occurrence of SRE subcomponents and their sequencing.
The 21-day window for grouping SRE subcomponents is
SRE SRE Identification Approach*
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Fig. 1 SRE identification approaches from claims
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accepted from a regulatory standpoint by the FDA and ap-
plied in RCTs [20–22]. It is not clear whether the 21-day
window used in RCTs is appropriate for identifying unique
SREs when using claims data.
Given the variability in the methods for studying SREs
using claims data, we undertook the present study in an
effort to better understand and clarify the impact of the
various approaches used in the identification of SREs
from administrative claim datasets. In particular, in this
paper we focus on the measurement of SRE prevalence
and cumulative incidence, both of which are commonly
measured in administrative claims data to answer clin-
ical and economic questions. We address SRE measure-
ment issues by analyzing two relevant questions. First,
what are the most appropriate and relevant claims to
use to identify SREs? Second, given the claims used, what
is the time period during which claims should be clus-
tered to represent one SRE episode? The potential for
overestimation or underestimation of SRE measures is a
function of the claims used and/or the time period used
to cluster the claims. For cumulative incidence, we
adopted the RCT 21-day window as the base case and
provide alternative measures by varying the window
length. The goal of this study is to provide a framework
for measuring SREs from claims and compare SRE
prevalence and cumulative incidence estimates based on
alternative measurement approaches using metastatic
prostate cancer (mPC) as a case study.
Methods
Data sources and sample selection
We estimated and compared prevalence and cumulative
incidence of SREs using the Surveillance, Epidemiology,
and End Results (SEER)—Medicare linked datasets. This
database links information from the National Cancer In-
stitute’s SEER cancer registries and the Centers for
Medicare and Medicaid Services Medicare claims data.
The SEER program collects cancer incidence and
mortality rates from 17 tumor registries across the U.S.
covering 28 % of the U.S. population (http://seer.cancer.-
gov/registries/data.html). The SEER data provides clin-
ical, demographic, and cause of death information for
patients diagnosed with cancer. In 2011, Medicare cov-
ered 93 % of the U.S. population aged 65 years or older
[23]. Medicare claims provide information on covered
health care services, including diagnosis and treatment
services, which are furnished to Medicare beneficiaries
from the time of Medicare eligibility until death.
This study included incident cases of mPC among pa-
tients aged 66 years or older diagnosed between 2000 and
2009. The study period ended upon health maintenance
organization (HMO) enrollment, Medicare Parts A and B
disenrollment, the patient’s death or December 31, 2010
(whichever occurred earlier). Patients were required to
have continuous enrollment in Medicare Parts A/B in the
year prior to mPC diagnosis in order to assess baseline
Charlson comorbidity index (CCI) in the year prior to
mPC diagnosis. Patients were excluded from the final
sample if they had history of cancer in the five years prior
to mPC diagnosis, if their diagnosis month or year was
unknown, or if they received a post mortem prostate can-
cer diagnosis. Patients with an SRE claim prior to mPC
diagnosis were also excluded since we were interested only
in SREs that were subsequent to mPC diagnosis.
Measures
Step One: SRE prevalence measure
Post-diagnosis SREs were identified using claims that indi-
cated PF, SCC, RAD, or BS. SRE types can be viewed either
as clinical events (i.e., PF and SCC) or treatment events
that can be administered to prevent a potential event or
treat a preceding clinical event (i.e., RAD or BS). Claims in-
volving SREs can be identified from two sets of codes; the
International Classification of Diseases 9th version Clinical
Modification (ICD-9-CM) and the Healthcare Common
Procedure Coding System (HCPCS). The ICD-9-CM is the
official system of assigning codes to hospital-related diag-
noses and procedures in the US. The HCPCS is a set of
health care procedure codes based on the American Med-
ical Association’s Current Procedure Terminology. We
identified clinical events (PF and SCC) using ICD-9-CM
diagnosis codes and treatment events (RAD and BS) using
ICD-9-CM procedure codes and HCPCS codes.
There is some uncertainty associated with identifying
SREs from claims because not all SREs can be specific-
ally identified from claims. Therefore, for each SRE, with
the exception of BS (since claims for this were clearly in-
dicative of a bone surgical procedure), we created two
lists of ICD-9-CM and HCPCS codes that indicated the
presence of that SRE subtype. The first list included
ICD-9-CM and HCPCS codes that were highly likely to
identify SREs (a ‘high specificity’ list), but which could
potentially result in underestimating SREs. The second
list included additional ICD-9-CM and HCPCS codes
that could identify additional SREs but may not neces-
sarily be as specific to the SRE type (a ‘high sensitivity’
list), and therefore had the potential to overestimate
SREs. Both lists were reviewed by a medical oncologist
and a radiation oncologist until consensus was reached
(see Appendix for details). From the ‘high specificity’
and ‘high sensitivity’ lists, we created two SRE defini-
tions. We propose a ‘base case’ SRE definition and pro-
vide an ‘alternative’ SRE definition by targeting either
sensitivity or specificity, depending on the SRE type.
For PF, the ‘high specificity’ list included only ICD-9-CM
Codes (733.1X) that specifically indicated “pathologic frac-
ture” on the claim, whereas the ‘high sensitivity’ list used
codes indicating a pathologic fracture or “other fracture” to
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maximize the identification of all fractures that may have
occurred due to cancer. This also accounts for the miscod-
ing potential commonly seen in measuring fractures [24].
However, with the exception of falls on the same level, we
excluded “other fracture” if it was associated with accidents
or falls within 14 days before the fracture because such
fractures are more likely to be associated with the preced-
ing accident or fall instead of weakening of the bone due to
cancer. Falls on the same level from routine activities, such
as walking or getting out of bed, were included in the study
since they are more likely to have been caused by a weaken-
ing of the bone due to cancer rather than having been
caused by the fall itself. The 14-day window used in the def-
inition of a PF has been used previously by other investiga-
tors [11, 13, 14, 17, 19]. The ‘base case’ SRE definition used
the PF ‘high sensitivity’ list because medical offices may use
“other fracture” codes instead of the more specific “patho-
logic fracture” codes to indicate a pathologic fracture [24].
For SCC, the ‘high specificity’ list included codes that
are commonly and specifically used in the literature to
identify SCC, which include unspecified disease of spinal
cord ICD-9-CM code 336.9 and HCPCS codes specific
to relieving pressure or decompression of the spinal
cord. In addition to these codes, the ‘high sensitivity’ list
included claims that indicated less specific codes that
may or may not indicate an SCC event, such as spondyl-
osis with myelopathy or intervertebral disc disorder with
myelopathy. The ‘base case’ SCC definition used the
‘high specificity’ list since many of the procedures in the
‘high sensitivity’ list were not specific to SCC treatment.
For the RAD measure, in Medicare claims there is no in-
dication as to whether radiation is administered to the
bone, to the primary cancer site (prostate gland) or to both
sites. Therefore, in an attempt to better characterize the
RAD measure for the purposes of the present study, we
categorized this measure by the type of radiation adminis-
tered, opting for radiation that is more likely to be used for
bone palliation compared to local control of disease within
the prostate gland. The types of external radiation included
in the claims data for men with M1 prostate cancer are: 2-
dimensional (2D) and 3-dimensional (3D) radiation, inten-
sity modulated radiation therapy (IMRT), and stereotactic
radiosurgery (SRS). Although there may be some outliers,
prior to 2009 use of SRS for bone metastasis was negligible,
and also likely to be quite low after 2009. Similarly, al-
though IMRTcan be used for bone metastasis, its use is still
quite uncommon for treating metastatic lesions to the bone
even in today’s clinical practice. On the other hand, SRS
and IMRT are more likely to be used to treat the prostate
than the bone (although this cannot be confirmed from
claims data) [25]. Thus, based on such assumptions, our
‘high specificity’ list for radiation to bone included ICD-9-
CM and HCPCS codes indicating delivery of 2D or 3D ex-
ternal beam radiation therapy (EBRT) and radioisotope use.
The ‘high sensitivity’ list, on the other hand, also includes
SRS and IMRT, in addition to 2D/3D radiation and radio-
isotopes. The ‘base case’ RAD definition used the ‘high spe-
cificity’ list of codes. In summary, the “base case” SRE
definition included codes identified under the ‘high specifi-
city’ lists of RAD and SCC and codes under the ‘high sensi-
tivity’ list of PF (in addition to all BS codes). The
“alternative” SRE definition included codes identified under
the ‘high specificity’ list of PF and codes under the ‘high
sensitivity’ lists of RAD and SCC (in addition to all BS
codes).
Step Two: SRE cumulative incidence
Step two requires clustering different SRE claims into
SRE episodes to calculate the cumulative incidence.
Therefore, a decision had to be made as to which code
definition to use for computing the SRE cumulative inci-
dence. We decided to use the base case code definition
since it represents the most commonly used approach in
the literature. Thus, when counting SREs, we used the
21-day window as the base case since this time period
was used in RCTs for measuring SREs. However, this
may not be the best approach when using claims since
the data capture utilization patterns and it is not clear
how to cluster utilization patterns for measuring distinct
SREs. Moreover, utilization patterns in the ‘real-world
setting’ may differ from the clinical trial setting in that
patients are more likely to delay care compared to those
enrolled in RCTs. Further, claims are generated for bill-
ing purposes and are not designed to reflect the exact
dates of service. Given these caveats, we therefore used
time periods that were ±7 days from the base case
window.
Analysis
For step one, we estimated the prevalence of SREs using
the two SRE definitions. We examined the frequency dis-
tributions between sociodemographic, clinical, and pros-
tate cancer-specific factors using the SRE ‘base case’ and
‘alternative’ SRE definitions. The second step was condi-
tional on using the ‘base case’ definition and involved esti-
mating the cumulative incidence of SREs using three time
periods, including 14-, 21-, and 28-day windows. All stat-
istical analyses were performed using SAS software pack-
age (version 9.3, SAS Institute, Cary, NC).
Results
Characteristics of study sample
The study sample included 8997 mPC patients with a
median age of 79 years and observed for a median of
1.5 years (range: 1 day–10 years). Table 1 shows the dis-
tribution of other sociodemographic, clinical, and
tumor-related characteristics categorized by SRE defin-
ition. Among the 8997 mPC patients, 4176 (46 %)
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experienced an SRE according to the ‘base case’ SRE def-
inition and 3851 (43 %) patients experienced an SRE ac-
cording to the ‘alternative’ SRE definition. The racial/
ethnic composition of the sample was predominantly
non-Hispanic White (75 %), with lower proportions of
non-Hispanic Blacks (15 %) and Hispanics (6 %).
SRE prevalence measure
Among the entire cohort, the proportion of patients with
RAD, PF, SCC, and BS were 30, 25, 10, and 8 %, respect-
ively. Of the 4176 patients with an SRE, the proportion of
patients with RAD, PF, SCC, and BS were 66, 53, 13, and
14 %, respectively. Table 2 presents how these estimates
change if the ‘alternative’ SRE definition was used. Varying
the code definition from ‘base case’ to ‘alternative’ resulted
in an 8 % increase in the overall SRE prevalence. Sixty nine
percent of mPC patients experienced more than one SRE
type during the 1.5 year median follow up period (Fig. 2).
SRE cumulative incidence measure
Cumulative incidence is defined as the number of SREs oc-
curring during the follow up period (median = 1.5 years).
Table 3 presents the impact of varying the window length
on the SRE cumulative incidence by SRE type. Using the
Table 1 Clinical and demographic characteristics of men with mPC according to code definition
Base case definition Alternative definition
Overall Yes No Yes No
(N = 8997) (N = 4176) (N = 4821) (N = 3851) (N = 5146)
N (%)a N (%)b N (%)b P value N (%)b N (%)b P value
Age 1528 17.0 803 52.6 725 47.4 <0.01 794 52.0 734 48.0 <0.01
66–70
71–75 1801 20.0 908 50.4 893 49.6 895 49.7 906 50.3
76–80 1995 22.2 942 47.2 1053 52.8 874 43.8 1121 56.2
80< 3673 40.8 1523 41.5 2150 58.5 1288 35.1 2385 64.9
Race/Ethnicity 6762 75.2 3274 48.4 3488 51.6 <0.01 3001 44.4 3761 55.6 <0.01
Non-Hispanic White
Non-Hispanic Black 1282 14.3 445 34.7 837 65.3 411 32.0 871 68.0
Hispanic 546 6.1 254 46.5 292 53.5 243 44.5 303 55.5
Other 407 4.4 203 49.9 204 50.1 196 48.2 211 51.8
Married 5216 58.0 2515 48.2 2701 51.8 <0.01 2385 45.7 2831 54.3 <0.01
Charlson Comorbidity Index 4871 54.1 2416 49.60 2455 50.40 <0.01 2280 46.81 2591 53.19 <0.01
0
1 1713 19.0 828 48.34 885 51.66 742 43.32 971 56.68
2 777 8.6 333 42.86 444 57.14 289 37.19 488 62.81
3+ 722 8.1 286 39.61 436 60.39 259 35.87 463 64.13
Missing 914 10.2 313 34.25 601 65.75 281 30.74 633 69.26
Poor Performance Status 1003 11.2 416 43.21 587 56.79 <0.01 350 37.34 653 62.66 <0.01
Gleason score <0.01 <0.01
2–6 206 2.3 78 37.86 128 62.14 77 37.38 129 62.62
7 663 7.4 287 43.29 376 56.71 285 42.99 378 57.01
8 771 8.6 355 46.04 416 53.96 335 43.45 436 56.55
9 1224 13.6 577 47.14 647 52.86 557 45.51 667 54.49
10 290 3.2 154 53.10 136 46.90 145 50.00 145 50.00
Not done/Unknown 5843 64.9 2725 46.64 3118 53.36 2452 41.96 3391 58.04
Poorly differentiated tumor 3423 38.1 1563 45.66 1860 54.34 0.06 1390 40.61 2033 59.39 <0.01
High PSA at baseline 7298 81.1 3415 46.79 3883 53.21 0.14 3185 43.64 4113 56.36 <0.01
Base case definition included codes identified under the ‘high specificity’ lists of RAD and SCC and codes under the ‘high sensitivity’ list of PF (in addition to all BS
codes); Alternative definition included codes identified under the ‘high specificity’ list of PF and codes under the ‘high sensitivity’ lists of RAD and SCC (in addition
to all BS codes). The Pearson χ2 was used to statistically test for significance of differences in the frequency distributions of categorical variables. A p value of
<0.05 was considered statistically significant
acolumn percent
brow percent
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21-day window, a total of 12,930 SRE episodes were ob-
served during follow up, with RAD, PF, SCC, and BS con-
stituting, respectively, 38, 50, 7, and 5 % of SRE episodes.
Varying the window length from 21 days to 28 days re-
sulted in an 8 % decrease in SRE cumulative incidence
(RAD: 10 %, PF: 8 %, SCC: 6 %, BS: 0.002 %). Varying the
window length from14 days to 28 days resulted in a 20 %
decrease in SRE cumulative incidence (RAD: 25 %, PF:
18 %, SCC: 16 %, BS: 0.1 %). The median (mean) number
of SREs experienced by mPC patients was 2 (3.1) events
during follow up. This was primarily driven by PF since the
median (mean) number of PF per patient was 2 (2.9) epi-
sodes. Each patient had a mean of 1.1 episodes of BS during
follow up.
The median (mean) time from mPC diagnosis to the
first SRE was 154 (335) days using the ‘base case’ defin-
ition and 133 (303) days using the ‘alternative’ definition.
In addition, the median (mean) time from the first SRE
to the second SRE was 21 (177) days using the ‘base
case’ definition and 26 (192) days using the ‘alternative’
definition. The median (mean) time from mPC diagnosis
to death was 566 (729) days using the ‘base case’ SRE
definition and 568 (734) days using the ‘alternative’ SRE
definition.
Discussion
The goal of the study was to quantify the differences in
prevalence and cumulative incidence of SREs based on
different measurement approaches for a clinically well-
defined population of men using health care claims data.
Our findings suggest that SRE prevalence and cumula-
tive incidence obtained from administrative claims data
can be affected by the methods used to estimate these
measures. For example, the prevalence of SREs varied
depending upon the types of ICD-9-CM and HCPCS
codes used to identify SREs from claims. While all SRE
subtypes were impacted by the codes used, PF was the
driver of the variability in the overall SRE prevalence.
Table 2 Prevalence of SRE among mPC men according to the ‘base case’ and ‘alternative’ code definitions
Base case definition Alternative definition
N % (of full cohort) % (of patients with at least 1 SRE) N % (of full cohort) % (of patients with at least 1 SRE)
PF 2202 24.5 % 52.7 % 1200 13.3 % 31.2 %
SCC 543 6 % 13 % 738 8.2 % 19.2 %
RAD 2736 30.4 % 65.5 % 2926 32.5 % 76 %
BSa 571 6.4 % 13.7 % 571 6.4 % 14.8 %
Any SRE 4176 46.4 % 100 % 3851 42.8 % 100 %
Base case definition included codes identified under the ‘high specificity’ lists of RAD and SCC and codes under the ‘high sensitivity’ list of PF (in addition to all
BS codes)
Alternative definition included codes identified under the ‘high specificity’ list of PF and codes under the ‘high sensitivity’ lists of RAD and SCC (in addition to all
BS codes)
SRE Skeletal Related Event, PF Pathological Fracture, SCC Spinal Cord Compression, RAD Bone Palliative Radiotherapy; BS Bone surgery
aOnly one set of codes was used for bone surgery
Fig. 2 Prevalence of SRE combinations among men diagnosed with mPC from 2000–2009
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Our findings also suggest that the window length used
to cluster SRE claims into a single SRE affects the cumu-
lative incidence of individual SREs, particularly RAD.
This may probably be the case because RAD is given in
cycles lasting generally for two to four weeks. Therefore,
it is not uncommon to observe multiple RAD claims in
a one-month period making the RAD measure highly
sensitive to the window length.
Given that metastasis to the bone from various cancers
is a major contributor to patient morbidity and mortal-
ity, significant efforts have been made to develop therap-
ies to mitigate and alleviate complications of bone
metastasis, known collectively as SREs. Significant pro-
gress has been made over the years with bone targeted
therapies, as determined by RCTs, which has led to the
widespread use of such therapies in advanced cancers.
To better understand the impact of these treatments
when applied outside the context of clinical trials, where
by necessity the experience is confined to limited num-
bers of patients who are rigorously selected, observa-
tional studies have proven invaluable. Despite some of
the inherent limitations associated with observational
studies, they provide important information when ther-
apies developed via RCTs are taken to the real world set-
ting and can help inform healthcare decisions and
policy. Therefore, using mPC as a model, we undertook
the present study to determine whether and how SRE-
related data may be affected by certain parameters, such
as codes and window lengths, that define the boundaries
of the SRE-related observational datasets.
Table 3 Cumulative incidence of SRE types according to window length
Maximum SRE Episode Length
14 days 21 days 28 days
Any Skeletal Related Event
Cumulative incidence (SRE/patient) 14,869 (3.6) 12,930 (3.1) 11,889 (2.8)
Patients with # SRE episodes
1 1320 (32) 1557 (37) 1705 (41)
2 955 (23) 967 (23) 969 (23)
3+ 1903 (46) 1652 (40) 1501 (36)
Pathologic Fracture
Cumulative incidence (PF/patient) 7342 (3.3) 6505 (2.9) 5990 (2.7)
Patients with # PF episodes (% of SRE Sample)
1 989 (45) 1046 (48) 1097 (50)
2 425 (19) 432 (20) 441 (20)
3+ 794 (36) 724 (33) 662 (30)
Spinal Cord Compression
Cumulative incidence (SCC/patient) 974 (1.8) 880 (1.6) 823 (1.5)
Patients with # SCC episodes (% of SRE Sample)
1 377 (70) 401 (74) 423 (78)
2 84 (15) 79 (15) 69 (12)
3+ 82 (15) 63 (11) 51 (10)
Bone Palliative Radiation
Cumulative incidence (RAD/patient) 5910 (2.2) 4907 (1.8) 4439 (1.6)
Patients with # RAD episodes (% of SRE Sample)
1 1143 (42) 1470 (54) 1662 (61)
2 822 (30) 741 (27) 686 (25)
3+ 771 (28) 525 (19) 388 (14)
Surgery to Bone
Cumulative incidence (BS/patient) 643 (1.1) 638 (1.1) 637 (1.1)
Patients with # BS episodes (% of SRE Sample)
1 510 (89) 514 (90) 515 (90)
2+ 61 (11) 57 (10) 56 (10)
SRE Skeletal related event, PF Pathological fracture, SCC Spinal cord compression, RAD Bone palliative radiotherapy; BS Bone surgery
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Investigators have used different approaches to iden-
tify SREs from claims. Figure 1 illustrates the various
approaches in the literature used to identify SREs from
claims. For PF, two approaches have been used. The
more specific approach was to use codes indicating
‘pathological fracture’ [15], while the second and more
sensitive approach was to use codes indicating ‘patho-
logical fracture’ or ‘other fracture’ (if there were no
concurrent claims with codes suggesting trauma or ac-
cident, excluding accident codes for routine activity
‘falls on the same level’) [11, 13, 14, 17, 19]. When
identifying SCC, some investigators exclusively used
‘unspecified disease of spinal cord’ diagnosis code [14, 19].
Others have included additional ICD-9-CM diagnosis
codes such as ‘spondylogenic compression’ and ‘interverte-
bral disc disorder with myelopathy’ and/or procedure
codes indicating ‘laminoplasty’ or ‘decompression of
spinal cord.’ [11, 15] For RAD, investigators who aimed
for high sensitivity included any claim indicating receipt
of radiation or a radiation-related procedure (examples
include ‘medical radiation physics consultation,’ ‘computed
tomography guidance for placement,’ and ‘radiation calcu-
lations’) [12]. On the other hand, investigators aiming for
higher specificity only used claims indicating radiation
delivery in the form of EBRT [17], sometimes with radio-
pharmaceuticals [14]. Some investigators required receipt
of RAD from a ‘radiation oncologist’ or a ‘therapeutic
radiologist’ [13]. Other investigators considered RAD only
when the claim was concurrent with a bone metastasis,
PF, SCC, or bone pain [11]. Similar to PF, some investiga-
tors required that BS be identified as an SRE if it was not
preceded by an accident or trauma in the 14 days prior to
the surgery [11]. Additionally, a few investigators have ad-
dressed the issue of how to handle multiple types of SRE
claims that occur on the same day by imposing a hierarchy
in which SREs viewed as clinical events (i.e., PF and
SCC) take precedence over SREs viewed as treatment
events (i.e., RAD and BS). For example, RAD or BS
would only be counted if there were no claims for
PF or SCC on the same day [11, 15]. Given the great
degree of variation in the approaches to identify dif-
ferent SRE types, this study investigates the conse-
quences of various approaches and quantifies the
variation in prevalence and cumulative incidence mea-
sures that can occur depending upon the approach used
to study such events.
This study has several limitations. The algorithms used
to identify SREs in this study have not been validated
and are subject to further research. In another setting, A
Danish study validated the ICD-10 coding of bone me-
tastasis and SREs in 100 prostate cancer patients in the
National Registry of Patients against medical chart re-
view data and found that the sensitivity of ICD-10 codes
ranged from 44–55 % and specificity ranged from 94–
100 %. The authors view these numbers to represent suf-
ficient sensitivity and high specificity. [26] Identifying
SREs from claims is not a straightforward task because
there is no billing code for SREs. The RAD measure rep-
resents a particular challenge for estimating the true
prevalence of RAD from claims data. This is evident by
the variability in the estimates using different claims and
is an important finding of this study. We believe the
main reason for that variability is that the RAD measure
may identify receipt of radiation as local treatment of
the prostate instead of the bone. We have attempted to
minimize the potential for overestimating the prevalence
by only assessing patients whose cancer has metastasized
and are therefore, more likely to have radiation adminis-
tered to metastatic sites. For patients with incident mPC,
the initial treatment tends to be androgen deprivation
therapy, with radiation to the primary site being less
likely (unless significant local complications such as
obstructive uropathy, hematuria or locoregional pain
occur from the cancer within the prostate gland dur-
ing the course of the disease). Thus, the RAD meas-
ure in Medicare claims among mPC patients is more
likely to reflect radiation therapy to treat bone metas-
tasis related issues. We also minimized the potential
for overestimation by identifying radiation techniques
more likely to be administered to the bone (EBRT
and radiopharmaceuticals) as opposed to the prostate
gland consistent with the literature [14, 17]. Among
patients with mPC, a small proportion may have oli-
gometastatic prostate cancer and may receive radi-
ation to the prostate with a curative intent [27].
However, these patients constitute very small numbers
and their inclusion in the study sample is not likely
to impact the findings. Nevertheless, the lack of radi-
ation site specifications in the claims data represents
some of the limitations inherent in the RAD measure
when using claims.
The PF measure can also pose challenges. While there
are specific ICD-9 diagnosis codes that indicate “patho-
logic fracture” and others that specifically indicate “other
fractures” in the ‘musculoskeletal and connective tissue
chapter’ of the ICD-9-CM handbook, there is confusion
as to which set of codes to include when defining
cancer-related fractures and osteoporosis-related frac-
tures. The definition of “pathologic fracture” according
to the American Hospital Association coding manual
used by physicians in the U.S. is a “break in a diseased
bone due to weakening of bone structure by pathologic
processes without identifiable trauma” (http://www.eicd.-
com/guidelines/default.htm). However, Curtis et al rec-
ommend including pathologic fractures in the definition
of osteoporosis-related fractures because physicians can
interpret one of the pathologic processes to be osteopor-
osis [24]. Similarly, there is a potential for oncologists to
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miscode pathologic fractures due to cancer as “other
fractures.” Therefore, for PF a more sensitive measure
may be more appropriate when using claims. For SCC,
the use of all procedure codes that involve decompres-
sion of the spinal cord, as well as the more specific diag-
nosis codes, may be more accurate since many of the
previously used diagnosis codes were not specific to
SREs. Additionally, this study did not include younger
patients (<66 years) diagnosed with incident mPC or
elderly patients who were initially diagnosed with non-
metastatic disease but developed bone metastasis during
follow up. Moreover, the study population included pa-
tients with M1 disease, not specifically M1b disease
making the denominator larger and potentially under-
estimating the true prevalence and cumulative incidence
of SREs.
Conclusions
Using different claims-based approaches to study the
burden of SREs can yield different estimates. We found
that SRE prevalence was affected by the codes used,
with PF being most impacted. The overall SRE cumula-
tive incidence was affected by the window length used,
with RAD being most affected. These results under-
score the importance of the baseline definitions used to
study claims data when attempting to understand rele-
vant clinical events such as SREs in the real world set-
ting. Over the past 30 years, both RCTs and
observational studies have played critical roles in
informing treatment decision making for patients with
mPC. Measurement approaches employed in RCT may
not translate readily to the observational study setting
when using health care claims data. In addition, the
patterns of utilization associated with clinically diag-
nosed conditions may differ between the trial and ob-
servational study setting, further complicating the task
of identifying SREs based on utilization data using ap-
proaches employed in RCTs. Anchoring on the ap-
proach used in the trial settings, we provide a proof of
concept investigation of the implications of different
measurement approaches for prevalence and cumula-
tive incidence estimates in a clinically well-defined
population of older men. Building on these findings to
develop validated algorithms for use in the observa-
tional study setting will bring needed consistency to the
measurement of SREs using administrative claims data.
A consistent approach for assessing SREs in adminis-
trative claims will not only improve comparability
across studies but also has the potential to address
questions relevant to comparative effectiveness re-
search in the area of bone metastasis.
Appendix
Table 4 ICD-9 and HCPCS codes used for base case (bolded)
and alternative SRE prevalence measures
SPINAL CORD COMPRESSION
ICD-9 3369, 7211, 7214, 72141, 72142, 72191, 7227, 72270, 72271 and
72273
HCPCS 63050, 63051, 22551, 22552, 63064, 63066, 61343, s2348,
63075-8, s2350, s2351, 63195, 63197, 63199, 63001, 63003,
63005, 63011, 63015, 63016, 63017, 63170, 63012, 63045,
63046, 63047, 63048, 63040, 63042, 63043, 63044, 63020,
63030, 63035, 22224, 22222, 22214, 22212, 22207, 22206,
0274t, 0275t, c9729, 0202t, 22865, 0164t, 0094t, 0097t,
63057, 63056, 63055, 63081, 63082, 63087, 63088, 63101,
63102, 63103, 63090, 63091, 63086, and 63085
PATHOLOGIC FRACTURES
ICD-9 7331, 73311, 73312, 73313, 73314, 73315, 73316, and
73319
HCPCS 8202, 8208, 8210, 8212, 73311, 8120, 8122, 8124, 73312, 8130,
8132, 8134, 8138, 73316, 8230, 8232, 8238, 73313, 805, 806, 8200,
7331, 73310, 73319, 800, 807, 8080, 8082, 8084, 8088, 8100, 8240,
8242, 80701, 80702, 80703, 80704, 80705, 80706, 80707, 80708,
80709, 80841, 80842, 80843, and 80849
TRAUMA/NON-ROUTINE FALLS / ACCIDENTS
ICD-9 819, 828, 851, 852, 853, 854, 860, 861, 862, 863, 864, 865, 866,
867, 868, 869, 8074, 9584, 80712, 80713, 80714, 80715, 80716,
80717, 80718, 80719, E800-E848, E881, E882, E883, E884.0, E884.1,
E884.5, E885.0, E885.1, E885.2, E885.3, E885.4, E886.0, E886.9,
E888.0, and E888.1
BONE PALLIATIVE RADIOTHERAPY
ICD-9 9223, 9224, 9229, 9230, 9231, 9232, and 9239
HCPCS A9600, A9604, A9605, C9401, G0173, G0174, G0243, G0251,
G0339, G0340, J3005, 0073 T, 61793, 61796, 61797, 61798,
63620, 63621,77371, 77372, 77373, 77401, 77402, 77403,
77404, 77406, 77407, 77408, 77409, 77411, 77412, 77413,
77414, 77416, 77418, 79005, 79101, 79200, 79300, 79400,
79403, 79440, 79445, and 79999
BONE SURGERY
ICD-9 7815, 7845, 7855, 7915, 7925, 7935, 7995, 7812, 7842,
7852, 7911, 7921, 7931, 7991, 7813, 7843, 7853, 7912,
7922, 7932, 7992, 7817, 7847, 7857, 7916, 7926, 7936,
7996, 0353, 8102, 8103, 8104, 8105, 8106, 8107, 8108,
7810, 7811, 7816, 7819, 7840, 7841, 7846, 7849, 7850,
7851, 7856, 7859, 7910, 7919, 7920, 7929, 7930, 7939,
7990, and 7999
HCPCS 27187, 27235, 27236, 27244, 27245, 27248, 27269, 27495,
27506, 27507, 27509, 27511, 27513, 27514, 23615, 23616,
23630, 24498, 24515, 24516, 24538, 24545, 24546, 24566,
24575, 24579, 24582, 24586, 24587, 24635, 24665, 24666,
24685, 25490, 25491, 25492, 25515, 25525, 25526, 25545,
25606, 25607, 25608, 25609, 27535, 27536, 27745, 27756,
27758, 27759, 27766, 27769, 27784, 27792, 27826, 27827,
22325, 22326, 22327, 22328, 22520, 22521, 22522, 22532,
22533, 22534, 22548, 22550, 22554, 22555, 22556, 22558,
22565, 22585, 22590, 22595, 22600, 22610, 22612, 22614,
22615, 22625, 22630, 22632, 20982, 23490, 23515, 23585,
27215, 27216, 27217, 27218, 27226, 27227, 27228, 27524,
27540, 22523, 22524, 22525, 22526, 22527, 25574, and
25575
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Abbreviations
2D: 2-dimensional; 3D: 3-dimensional; BS: Bone surgery; CCI: Charlson
comorbidity index; EBRT: External beam radiation therapy; FDA: Food and
Drug Administration; HCPCS: Healthcare Common Procedure Coding System;
HMO: Health maintenance organization; ICD-9-CM: International Classification
of Diseases 9th version Clinical Modification; IMRT: Intensity modulated
radiation therapy; mPC: Metastatic prostate cancer; PF: Pathologic fracture;
RAD: Bone palliative radiotherapy; RCT: Randomized clinical trial; SCC: Spinal
cord compression; SEER: Surveillance, Epidemiology, and End Results;
SRE: Skeletal related event; SRS: Stereotactic radiosurgery.
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